Jorrit is involved in all projects.
Helene Knævelsrud
- Visiting scientist
- +47 22 78 19 65
Helene leads a project group centered around two main goals 1) to understand how autophagy is turned off - and how this impacts physiology and cancer 2) to identify novel therapies for MLL-rearranged leukemia with the help of a fruit fly model of leukemia.
Pilar Ayuda-Durán
- Postdoc
- +47 22 78 19 70
Pilar joined the Enserink group as a post-doctoral researcher in January 2014 with a 2-years grant funded by the Fundación Alfonso Martín Escudero. She works in a personalized-medicine platform for leukemia patients, testing the sensitivity of primary cells from patients or healthy donors to a panel of anticancer drugs.
Robert Hanes
- Postdoc
- +47 22 78 18 46
Robert joined the Enserink group in October 2017. He is working on the identification and development of novel and personalized treatment strategies for leukemia through computational analysis of high-throughput data from drug sensitivity screens and various omics-based technologies.
Nathalia Chica
- Researcher
- +47 22 78 19 66
Nathalia's work is to develop and establish a genome-wide study in autophagy using budding yeast to further understand autophagy dynamic response in higher eukaryotes.
Mary-Ann Jallad
- Postdoc
- +47 22 78 19 60
Mary-Ann joined the group in June 2021 and is working on identifying synergizing drug combinations for the treatment of breast cancer using a high-throughput drug screening platform and validating them on patient derived xenografts.
Niveditha Umesh Katyayini
- Postdoc
- +47 22 78 19 61
Niveditha joined the group in May 2021 as Research assistant. She supports the project for the development of new immunotherapies for cancer patients.
Jeanne G. Corrales
- Ph.D. student
- +47 22 78 19 73
Jeanne is working on the development of new antimycotics to treat drug-resistant fungal infections. She started her PhD. project with Nacho Garcia in 2019.
Andrea Moen Brodersen
- Ph.D. student
- +47 22 78 19 59
Andrea is looking into improving systems for personalized medicine in lung cancer through the use of 3D cell cultures and machine learning strategies.
